尿路感染症に対するCeftzole(CTZ)の臨床的検討

Abstract

Ceftezole (CTZ), a new cephalosporin antibiotic, was clinically evaluated in urinary tract infections including chronic complicated UTI. Clinical data were analysed and evaluated based on "Criteria for clinical evaluation of antimicrobial agent on UTI". The results obtained were as follows: 1) Ceftezole was administered twice daily to 20 cases, 2 cases with acute simple UTI and 18 cases with chronic complicated UTI, at a dose of 4000 mg per day by intravenous injection for several days. Overall clinical efficacy was found to be excellent in one case, good in 8, poor in 2 and unevaluated in 9. Effective ratio was 81.8%. Poor effective cases were only found in the indwelling catheter group. 2) In sensitivity test using disc, 2 strains out of 3 in Proteus and 2 out of 2 in Pseudomonas were not susceptible to CTZ. All of isolated strains in E. coli, Klebsiella, Staphylococcus and Streptococcus were susceptible. 3) Bacteriological response was found in 15 strains out of isolated 20 strains. Tendency to poor response was found in Serratia, Pseudomonas and Proteus. 4) No allergic reaction was observed. Slight elevation of serum transaminase values without symptom was found in 2 cases, whose elevation was transient and normalized with discontinuance of drug. Jaundice, malaise and remarkable elevation of serum transaminase were found in one case during administration. In this case, however, HBs-antigen was positive probably due to previous blood transfusion. These findings obviously suggested viral hepatitis unrelated to drug administration.